265 related articles for article (PubMed ID: 18634782)
1. The role of the N-terminal and mid-region residues of substance P in regulating functional selectivity at the tachykinin NK1 receptor.
Perrine SA; Beard DJ; Young JK; Simmons MA
Eur J Pharmacol; 2008 Sep; 592(1-3):1-6. PubMed ID: 18634782
[TBL] [Abstract][Full Text] [Related]
2. Functional selectivity of NK1 receptor signaling: peptide agonists can preferentially produce receptor activation or desensitization.
Simmons MA
J Pharmacol Exp Ther; 2006 Nov; 319(2):907-13. PubMed ID: 16916996
[TBL] [Abstract][Full Text] [Related]
3. Conformational comparisons of a series of tachykinin peptide analogs.
Beard DJ; Perrine SA; Phillips E; Hoque S; Conerly S; Tichenor C; Simmons MA; Young JK
J Med Chem; 2007 Dec; 50(26):6501-6. PubMed ID: 18067242
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a conformationally sensitive TOAC spin-labeled substance P.
Shafer AM; Nakaie CR; Deupi X; Bennett VJ; Voss JC
Peptides; 2008 Nov; 29(11):1919-29. PubMed ID: 18775458
[TBL] [Abstract][Full Text] [Related]
5. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
Ciucci A; Palma C; Manzini S; Werge TM
Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
[TBL] [Abstract][Full Text] [Related]
6. Determination of the amino acid residues in substance P conferring selectivity and specificity for the rat neurokinin receptors.
Cascieri MA; Huang RR; Fong TM; Cheung AH; Sadowski S; Ber E; Strader CD
Mol Pharmacol; 1992 Jun; 41(6):1096-9. PubMed ID: 1377326
[TBL] [Abstract][Full Text] [Related]
7. The N-terminal domain of human hemokinin-1 influences functional selectivity property for tachykinin receptor neurokinin-1.
Mou L; Xing Y; Kong Z; Zhou Y; Chen Z; Wang R
Biochem Pharmacol; 2011 Mar; 81(5):661-8. PubMed ID: 21168392
[TBL] [Abstract][Full Text] [Related]
8. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
[TBL] [Abstract][Full Text] [Related]
9. Systematic study of substance P analogs. II. Rapid screening of 512 substance P stereoisomers for binding to NK1 receptor.
Wang JX; Dipasquale AJ; Bray AM; Maeji NJ; Spellmeyer DC; Geysen HM
Int J Pept Protein Res; 1993 Oct; 42(4):392-9. PubMed ID: 7503964
[TBL] [Abstract][Full Text] [Related]
10. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
[TBL] [Abstract][Full Text] [Related]
11. Conformational analysis of the C-terminal Gly-Leu-Met-NH2 tripeptide of substance P bound to the NK-1 receptor.
Sagan S; Quancard J; Lequin O; Karoyan P; Chassaing G; Lavielle S
Chem Biol; 2005 May; 12(5):555-65. PubMed ID: 15911376
[TBL] [Abstract][Full Text] [Related]
12. The N-terminal domain of substance P is required for complete homologous desensitization but not phosphorylation of the rat neurokinin-1 receptor.
Vigna SR
Neuropeptides; 2001 Feb; 35(1):24-31. PubMed ID: 11346307
[TBL] [Abstract][Full Text] [Related]
13. Systematic study of substance P analogs. I. Evaluation of peptides synthesized by the multipin method for quantitative receptor binding assay.
Wang JX; Bray AM; Dipasquale AJ; Maeji NJ; Geysen HM
Int J Pept Protein Res; 1993 Oct; 42(4):384-91. PubMed ID: 7503963
[TBL] [Abstract][Full Text] [Related]
14. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin-1 receptor resensitization precedes receptor recycling.
Bennett VJ; Perrine SA; Simmons MA
J Pharmacol Exp Ther; 2005 Jun; 313(3):1347-54. PubMed ID: 15764733
[TBL] [Abstract][Full Text] [Related]
16. Presence of NK1 receptors on a mucosal-like mast cell line, RBL-2H3 cells.
Cooke HJ; Fox P; Alferes L; Fox CC; Wolfe SA
Can J Physiol Pharmacol; 1998 Feb; 76(2):188-93. PubMed ID: 9635159
[TBL] [Abstract][Full Text] [Related]
17. Characterization of ligand-binding properties and selectivities of three rat tachykinin receptors by transfection and functional expression of their cloned cDNAs in mammalian cells.
Ingi T; Kitajima Y; Minamitake Y; Nakanishi S
J Pharmacol Exp Ther; 1991 Dec; 259(3):968-75. PubMed ID: 1662278
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M
Neuro Endocrinol Lett; 2005 Aug; 26(4):367-72. PubMed ID: 16136007
[TBL] [Abstract][Full Text] [Related]
19. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
